Thus, our results (overexpression of MARCKS in IBC versus non-IBC, association with poor-prognosis variables in breast cancers, unfavorable independent prognostic value in IBC) are consistent with the clinical and pre-clinical findings published in breast cancer and other cancers (colorectal, ovarian, lung, cholangiocarcinoma, melanoma). This evidence concerns the gene MARCKS and breast carcinoma.